Related Experiment Video
Updated: May 4, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Immune-Related Adverse Events in a Patient With Burkitt's Lymphoma During PD-1 Immune Consolidation Therapy: A Case
Qi Zhang1, Fankai Meng1, Yang Cao1
1Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Abstract:
A patient with Burkitt's lymphoma developed upper gastrointestinal adverse events during immune consolidation therapy following chemotherapy combined with autologous stem cell transplantation. Subsequent administration of vedolizumab as adjunctive therapy resulted in improvement of the patient's symptoms. This case is expected to provide a reference for the expanded application of PD-1 inhibitors in non-Hodgkin's lymphoma.

